Key clinical point: Minimal residual disease (MRD) negativity was linked to survival benefits in multiple myeloma patients undergoing autologous transplantation.
Major finding: Progression-free survival was significantly increased for patients who were MRD negative at baseline, pre-lenalidomide maintenance, and 1-year post transplant, while overall survival was significantly improved based on MRD status measured at the 1-year time point.
Study details: Results of the ancillary study known as PRIMeR (Prognostic Immunophenotyping for Myeloma Response), including 445 patients from the STAMiNA trial who underwent MRD assessment at three time points.
Disclosures: Dr. Hahn reported research funding from Celgene and the National Institutes of Health.
Hahn TE et al. TCT 2019, Abstract 6.